| IgA-CCP2 | IgG-CCP2 | IgM-CCP2 |
---|
Controls (n = 276)a | 0.8 | 1.2 | 18.5 |
(IQR) | (0.5 to 1.1) | (0.8 to 2.1) | (11.1 to 34.3) |
Pre-patients (n = 71)b | 1.1* | 3.4 ** | 21.6 * |
(IQR) | (0.6 to 2.1) | (1.2 to 55.0) | (10.1 to 55.3) |
Patients (n = 53)c | 1.8*** | 14.0 *** | 51.9*** |
(IQR) | (0.9 to 6.8) | (11.4 to 715.5) | (29.8 to 127.0) |
p value1 | <0.001 | <0.001 | <0.001 |
- a Analysis of IgM; n = 263 controls b, Analysis of IgM; n = 68 pre-patient samples, cAnalysis of IgA; n = 54 and of IgG-CCP2; n = 59, * P < 0.05, ** P < 0.01, ***P < 0.001 pre-patients vs. controls or RA patients vs. controls,1P-values obtained from Kruskal-Wallis analysis comparing all three groups. Anti-CCP, anti-cyclic citrullinated peptide; IQR, inter quartile range; Ig, immunoglobulin.